StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
300233.SZ$13.44+2.28%
Fair $13.44+0.0%

300233.SZ

Shandong Jincheng Pharmaceutical Group Co., Ltd

Basic Materials / ChemicalsShenzhen

$13.44

+0.30 (+2.28%)

Fairly Valued+0.0%Fair Value $13.44Fund rank 32/100 · Data gapFallback financials|
SA 38/D
F-Score: 4/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 23%

FCF escenarios

weak_data · normalized FCF $218.8M · quality 56.7/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 34/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Revenue has declined for 2 consecutive years ROE is 1.2%, below the 5% threshold
Thesis & Journal · 300233.SZLocal privado en este navegador · Shandong Jincheng Pharmaceutical Group Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.2B

P/E

74.7x

↑

EV/EBITDA

11.0x

↑

ROE

1.2%

↑

Gross Margin

36.0%

↑

Debt/Equity

0.10

↓
52-Week Range$13
$13$22

TradingView lightweight chart

300233.SZ price, volumen y niveles de valoración

Último $13.44Periodo +32.0%
Fair value: $13.44

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.9%

FCF CAGR

—

FCF margin

8.0%

FCF / Net income

4.95x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.74B · net income $44.2M · FCF $218.8M

2022-FY → 2025-FY

Gross margin

36.0%-10.2% pts

Operating margin

5.0%-6.6% pts

Net margin

1.6%-6.2% pts

FCF margin

8.0%+11.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.74B$2.74B$3.37B$3.54B$3.51B
Net Income$44.2M$44.2M$196.8M$174.7M$273.4M
EBITDA$410.3M$410.3M$606.2M$558.5M$628.6M
EPS0.120.120.520.450.71
Gross Margin36.0%36.0%40.1%43.7%46.2%
Operating Margin5.0%5.0%8.8%8.2%11.6%
Net Margin1.6%1.6%5.8%4.9%7.8%
Balance Sheet
Debt/Equity0.100.100.140.150.18
Current Ratio1.731.73———
Cash Flow
Free Cash Flow$218.8M$218.8M$154.0M$321.2M$-118.0M
Returns
ROE1.2%1.2%5.2%4.7%7.6%
Valuation
P/E74.6774.6722.2936.0932.87
EV/EBITDA10.9710.976.5710.4513.97
P/B1.351.351.161.702.49
Growth & Yield
Revenue Growth-18.9%-18.9%-4.7%0.9%—
EPS Growth-76.9%-76.9%15.6%-36.6%—
Dividend Yield1.9%1.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

115.0%

muy exigente

EPS terminal req.

$1.19

Spread vs growth

-191.9%

5Y implied EPS CAGR

64.4%

muy exigente

EPS terminal req.

$1.44

Spread vs growth

-141.4%

10Y implied EPS CAGR

34.5%

muy exigente

EPS terminal req.

$2.32

Spread vs growth

-111.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -13.6%

Total return

-13.6%

Start / end P/E

30.6x → 112.0x

EPS bridge

0.52 → 0.12

Residual

-205.0%

EPS growth-76.9%
Multiple rerating+266.5%
Dividend+1.9%
Residual / FX / buybacks / cross-term-205.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.